170 Participants Needed

Genetics Navigator for Genetic Conditions

Recruiting at 2 trial locations
MC
Overseen ByMarc Clausen, MA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Unity Health Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on genetic testing and does not mention medication changes.

What data supports the effectiveness of the treatment Genetics Navigator for Genetic Conditions?

Research shows that digital tools in genetic services, like Genetics Navigator, can improve patient knowledge, well-being, and engagement, while also making healthcare more efficient. These tools help patients understand their genetic information better and communicate more effectively with healthcare providers.12345

What safety data exists for Genetics Navigator in humans?

Human genetics research can help identify potential safety risks of new treatments by studying genetic variants that model the effects of these treatments over a lifetime. This approach can predict possible adverse effects and improve the safety assessment of new drugs, even if animal models are not available.678910

How is the Genetics Navigator treatment different from other treatments for genetic conditions?

The Genetics Navigator treatment is unique because it integrates both genetic and phenotypic data to diagnose genetic disorders, using advanced methods like ACMG-Bayes and phenotypic similarity. This approach allows for a more comprehensive analysis compared to traditional methods that often rely solely on genetic sequencing.1112131415

Research Team

YB

Yvonne Bombard, PhD

Principal Investigator

St. Michael's Hospital and University of Toronto

RH

Robin Hayeems, PhD

Principal Investigator

The Hospital for Sick Children and University of Toronto

Eligibility Criteria

This trial is for patients or parents of patients with neurodevelopmental disorders, retinal disease, connective tissue disease, cardiac conditions, or childhood epilepsy who are being offered genetic testing. It aims to evaluate a digital platform called Genetics Navigator.

Inclusion Criteria

I am 18 or older and referred for genetic testing at UHN.
I am the parent or legal guardian of a child referred for genetic testing at SickKids.

Exclusion Criteria

I am not eligible for genetic testing in Ontario.
I need urgent genetic testing.
I am not fluent in English.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants in the intervention arm will use the Genetics Navigator to support the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations.

9 months
In-person/phone/video-conferencing consults

Control

Participants in the control arm will receive their genetic counselling and test results through usual care, which consists of in-person/phone/video-conference consults with genetic counsellors and medical geneticists.

9 months
In-person/phone/video-conferencing consults

Follow-up

Participants are monitored for safety and effectiveness after treatment

9 months

Treatment Details

Interventions

  • Genetics Navigator
Trial Overview The study compares the use of the Genetics Navigator—a digital support tool for genetic service delivery—with standard care provided by genetics professionals. The goal is to see if it reduces distress and improves patient experience.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Genetics NavigatorExperimental Treatment1 Intervention
Participants in the intervention arm will use the Genetics Navigator to support the delivery of genetic services, including intake, education, pre- and post-test counselling, return of results, and physician-generated management recommendations. Participants in the experimental arm will also receive standard of care genetics care.
Group II: Standard Care with Genetics ProfessionalsActive Control1 Intervention
Participants in the control arm will receive their genetic counselling and test results through usual care, which consists of in-person/phone/video-conference consults with genetic counsellors and medical geneticists.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Unity Health Toronto

Lead Sponsor

Trials
572
Recruited
470,000+

Findings from Research

A systematic review of 87 studies found that 84% reported positive outcomes for patients using digital genetics tools, enhancing knowledge, psychosocial well-being, and engagement in genetic service delivery.
Digital tools not only improved patient outcomes but also increased workflow efficiency for healthcare providers, suggesting they can effectively support patient-centered care in the growing demand for genetic services.
Patient-facing digital tools for delivering genetic services: a systematic review.Whiwon, L., Salma, S., Daniel, A., et al.[2023]

References

Patient-facing digital tools for delivering genetic services: a systematic review. [2023]
Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery. [2022]
Outcome measures for clinical genetics services: a comparison of genetics healthcare professionals and patients' views. [2022]
Characterization of variant reclassification and patient re-contact in a cancer genetics clinic. [2022]
Impact of a Patient-Facing Enhanced Genomic Results Report to Improve Understanding, Engagement, and Communication. [2022]
Using human genetics to improve safety assessment of therapeutics. [2023]
Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. [2021]
Using pharmacogenetics knowledge to increase accuracy of alerts for adverse drug events. [2018]
The Longitudinal Pediatric Data Resource: Facilitating Longitudinal Collection of Health Information to Inform Clinical Care and Guide Newborn Screening Efforts. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Utility and limitations of genetic disease databases in clinical genetics research: a neurofibromatosis 1 database example. [2008]
GFINDer: genetic disease and phenotype location statistical analysis and mining of dynamically annotated gene lists. [2019]
The LOVD3 platform: efficient genome-wide sharing of genetic variants. [2022]
diseaseGPS: auxiliary diagnostic system for genetic disorders based on genotype and phenotype. [2023]
14.United Statespubmed.ncbi.nlm.nih.gov
Graphical visualization and navigation of genetic disease information. [2019]
PhenGenVar: A User-Friendly Genetic Variant Detection and Visualization Tool for Precision Medicine. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security